skip to main contentskip to main menuskip to footer Universität Bielefeld Play Search
  • Or­ga­nic Che­mi­s­try OC3 - Prof. Se­wald

    © Uni­ver­si­tät Bie­le­feld

Wel­co­me to the Or­ga­nic and Bio­or­ga­nic Che­mi­s­try work group!

Che­mi­s­try­View high­lights our fin­dings on en­zy­ma­tic bro­mi­na­ti­on of pro­te­ins

Che­mi­s­try­View high­lights our fin­dings on en­zy­ma­tic ha­lo­ge­na­ti­on of pro­te­ins at C-​terminal tryp­tophan pu­blished in An­ge­wand­te Che­mie. An en­gi­nee­red va­ri­ant of the Trp 6-​halogenase Thal al­lows post-​translational bro­mi­na­ti­on of a te­tra­pep­ti­de tag with C-​terminal tryp­tophan in pro­te­ins on a pre­pa­ra­ti­ve scale using the bromi­na­ting E. coli co­ex­pres­si­on strain Bro­co­li. The bro­mo­are­ne can be de­ri­va­ti­zed by palladium-​catalyzed Su­zu­ki–Mi­yau­ra cross-​coupling at 37 °C. This opens new ave­nues for bio-​orthogonal mo­di­fi­ca­ti­on of pro­te­ins by bio­ca­ta­ly­tic bro­mi­na­ti­on of mi­ni­mal­ly tag­ged pro­te­ins.

The ar­ti­cle from Che­mi­s­try­View can be found here.

 

Jörg Schwarz­bich In­ven­tor Award for new can­cer drug

© Uni­ver­si­tät Bie­le­feld/Ste­fan Sät­te­le

In re­co­gni­ti­on of his ground­brea­king in­no­va­tions, che­mist Pro­fes­sor Dr. Nor­bert Se­wald is awar­ded the Jörg Schwarz­bich In­ven­tor Award this year. This award ho­nors his out­stan­ding con­tri­bu­ti­ons to basic re­se­arch in the field of can­cer me­di­ca­ti­ons. The Uni­ver­si­ty So­cie­ty Bie­le­feld (UGBi), in close col­la­bo­ra­ti­on with Bie­le­feld Uni­ver­si­ty, pres­ents this honor, which comes with a prize of 40,000 euros. Nor­bert Se­wald and his team have suc­cess­ful­ly de­ve­lo­ped a novel and high­ly po­tent drug that selec­tive­ly tar­gets tumor tis­sue, while af­fec­ting healt­hy cells to a si­gni­fi­cant­ly les­ser ex­tent. This ap­proach en­han­ces the ef­fec­ti­ve­n­ess of the tre­at­ment while si­mul­ta­ne­ous­ly im­pro­ving its to­le­ra­bi­li­ty.

More in­for­ma­ti­on can be found here.

 

In­ter­view with Hertz 87.9 about the Jörg Schwarz­bich In­ven­tor Award

In a con­ver­sa­ti­on with Hertz 87.9, Nor­bert Se­wald dis­cus­ses his mo­ti­va­ti­on in can­cer re­se­arch, the po­ten­ti­al ti­me­frame until the ap­p­li­ca­ti­on of the new drug as a can­cer me­di­ca­ti­on in cli­nics, and the fu­ture plans for his re­se­arch and his team.

The in­ter­view can be found here.

Ma­gicbul­let::Reloa­ded

Sur­ge­ry, ra­dia­ti­on, and che­mo­the­ra­py are the three main the­ra­pies used to treat can­cerous tu­mors. The doc­to­ral re­se­arch net­work ‘Ma­gicbul­let::Reloa­ded’ is in­ves­ti­ga­ting ano­ther ap­proach, with 15 doc­to­ral re­se­ar­chers de­ve­lo­ping spe­cial mole­cu­les that sti­mu­la­te the im­mu­ne sys­tem to de­s­troy tumor cells.

Ya­Bi­Na­PA at Re­se­arch_TV

When peop­le in Ca­mer­oon suf­fer from ma­la­ria and other pa­ra­si­tic in­fec­tious di­sea­ses, they often can­not af­ford tre­at­ment – the im­por­ted syn­the­tic me­di­ci­nes cost a lot of money. The gra­dua­te school Ya­Bi­Na­PA of Bie­le­feld Uni­ver­si­ty and the Uni­ver­si­ty Yaoundé I in Ca­mer­oon aims to re­me­dy this. re­se­arch_tv pres­ents the pro­ject.

Ma­gicbul­let at Re­se­arch_TV

How do ac­ti­ve sub­stances have to be struc­tu­red in order to tar­get can­cer cells selec­tive­ly? Fif­teen doc­to­ral stu­dents in the “Ma­gicbul­let” net­work have spent three years con­duc­ting re­se­arch into this.

Ne­west Pu­bli­ca­ti­on

Zum Seitenanfang
© Uni­ver­si­tät Bie­le­feld/Ste­fan Sät­te­le

Datenschutzeinstellung

Diese Webseite verwendet Cookies und ähnliche Technologien. Einige davon sind essentiell, um die Funktionalität der Website zu gewährleisten, während andere uns helfen, die Website und Ihre Erfahrung zu verbessern. Falls Sie zustimmen, verwenden wir Cookies und Daten auch, um Ihre Interaktionen mit unserer Webseite zu messen. Sie können Ihre Einwilligung jederzeit unter Datenschutzerklärung einsehen und mit der Wirkung für die Zukunft widerrufen. Auf der Seite finden Sie auch zusätzliche Informationen zu den verwendeten Cookies und Technologien.